SecBot SecBot

ARQT drug pipeline

$28.26
+2.6% 1-day · Nov 13
Next catalyst
Feb 23, 2027
ZORYVE PDUFA date · in 99 days
Typical move on FDA news
±2.9%
1-day, median of 6 events
IV rank
42
IV 65% · HV 93%
Rated drugs
1
1 bullish
Phase 3 trials
2
1 with results posted

Upcoming catalysts

1 dated
  1. Feb 23, 202799d
    ZORYVE
    PDUFA date · mild to moderate atopic dermatitis in infants aged 3 to 24 months

Drugs

soonest catalyst first
▲ bullish
Impact
PhaseApproved (commercial stage)
Time to marketAlready approved and commercialized. The next label expansion (infant atopic dermatitis) has a PDUFA decision date of February 23, 2027.

ZORYVE roflumilast Updated Nov 13

99days
Next catalyst
PDUFA date · Feb 23, 2027 · mild to moderate atopic dermatitis in infants aged 3 to 24 months
What to watch

The next hard catalyst is the FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis. Approval would expand the addressable patient population and support the company's 2027 revenue inflection narrative; a CRL would remove that near-term growth driver but not threaten the core commercial business, which is already generating over $500M in annual revenue.

Bull case
  • Strong commercial momentum: ZORYVE net product revenue reached $143.9M in Q3 2026, up 45% year-over-year and 11% sequentially, with full-year 2026 guidance raised to $535-545 million.
  • Expanding label: ZORYVE is now approved across three major inflammatory skin conditions (plaque psoriasis, atopic dermatitis, seborrheic dermatitis) with multiple formulations (cream 0.3%, 0.15%, 0.05% and foam 0.3%), making it the #1 prescribed branded topical therapy across these indications.
  • Upcoming PDUFA catalyst: The FDA accepted the sNDA for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis, with a PDUFA date of February 23, 2027, which could open a new patient population.
Bear case
  • Insider selling: Multiple executives (CEO Todd Watanabe, CMO Patrick Burnett, CLO Masaru Matsuda) sold shares in early November 2026 near $31-34, near the top of the 52-week range, per SEC Form 4 filings.
  • EPS miss: Arcutis missed Q3 2026 earnings expectations as SG&A spending jumped to $99.6M (from $62.4M a year ago) to fund sales force expansion, pressuring near-term profitability.
  • Competitive pressure: ZORYVE faces competition from topical steroids, other PDE4 inhibitors, and JAK inhibitors in dermatology; a Seeking Alpha analyst downgraded the stock to Hold citing intense competition and slow growth.

Other drugs in filings and trials

no drug report yet

Past FDA events & how the stock moved

6 events
DateDrugEvent1 day5 days
Jun 30, 2026ZORYVENDA filed−3.4%+6.5%
Jun 29, 2026ZORYVENDA filed−2.9%+2.5%
Jun 29, 2026ZORYVEPDUFA decision−2.9%+2.5%
Jan 1, 2026ZORYVENDA filed−0.1%+2.9%
Dec 15, 2023ZORYVEApproval0.0%+16.5%
Jul 29, 2022ZORYVEApproval−13.3%+7.7%

Clinical trials

4 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Topical roflumilast 0.3% foamA Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis SuppurativaPhase 2Completed10Sep 28, 2026
ZORYVEA 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)Phase 3Terminated3,973Dec 23, 2025
Topical roflumilastOpen-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisPhase 3Completed · results337Jan 22, 2024
ARQ-151 cream 0.3%Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)Phase 2Completed · results10May 11, 2022